Hydroxychloroquine and Indapamide in SPMS

Summary

The purpose of this clinical trial is to determine if HCQ in a dose of 400mg daily and indapamide in a dose of 2.5mg daily can help in reducing the progression of disability in people with secondary progressive multiple sclerosis. The number of participants in this study will be 35. A maximum of 42 people with SPMS will be included. The trial is funded through internal funding through the University of Calgary. There is no sponsorship from any pharmaceutical industry.

Timeline

Start

2021-10-01

Primary completion

2023-09-01

Completion

2024-09-01

Drugs

Indications